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Abstract: P14ARF is a tumor suppressor encoded by the CDKN2a locus that is frequently inactivated
in human tumors. P14ARF protein quenches oncogene stimuli by inhibiting cell cycle progression
and inducing apoptosis. P14ARF functions can be played through interactions with several proteins.
However, the majority of its activities are notoriously mediated by the p53 protein. Interestingly,
recent studies suggest a new role of p14ARF in the maintenance of chromosome stability. Here, we
deepened this new facet of p14ARF which we believe is relevant to its tumor suppressive role in
the cell. To this aim, we generated a monoclonal HCT116 cell line expressing the p14ARF cDNA cloned
in the piggyback vector and then induced aneuploidy by treating HCT116 cells with the CENP-E
inhibitor GSK923295. P14ARF ectopic re-expression restored the near-diploid phenotype of HCT116
cells, confirming that p14ARF counteracts aneuploid cell generation/proliferation.
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The alternate open reading frame (ARF) gene was originally identified as an alternative transcript
of the CDKN2a locus on human chromosome 9p21 that encodes the nucleolar protein p14ARF which
has a potent tumor suppressor activity. Loss of the CDKN2a locus is the second most frequent copy
number alteration that characterizes human tumors and cancer cell lines. One of the most well-defined
functions of p14ARF protein is to suppress aberrant cell proliferation in response to oncogene insults by
activating the transcription factor p53 that, in turn, triggers the expression of many apoptosis inducers
and cell cycle inhibitory genes [1]. In the presence of oncogenic stimuli p14ARF binds the p53-specific
E3 ubiquitin ligase Mouse double minute 2 homolog (Mdm2) and keeps it in the nucleolus. This
event prevents the interaction between Mdm2 and p53 by blocking the transport to the cytoplasm
of p53 and its degradation by the proteasome Mdm2-mediated [1–3]. ARF is also able to inhibit
the ubiquitin ligase activity of ARF-BP1/Mule protein. It has been reported that in p53 wild-type cells
ARF-BP1 directly binds and ubiquitinates p53, and inactivation of endogenous ARF-BP1 is crucial for
ARF-mediated p53 stabilization [4].
On the other hand, there is some evidence that ARF, especially its small mitochondrial isoform
(smARF) [5], also has the ability to restrain cell growth independently of the presence of the p53 protein.
The Zambetti group showed that triple knockout mice lacking ARF, p53, and MDM2 genes were more
tumour prone when compared to mice lacking only p53 and MDM2 [6]. In addition and in line with
this result they showed that ARF overexpression can induce the arrest in the G1 phase of the cell
cycle in cells lacking p53 [6]. Moreover, ARF through interaction with a multitude of different target
proteins (i.e., NPM1, E2F, Myc) regulates mitochondrial activity, autophagy, sumoylation, transcription
activities, specific protein turnover, and ribosome biogenesis, leading to cell cycle arrest and senescence,
as reviewed by Ko and colleagues [7]. The importance of the role of p14ARF is highlighted by the effect
of its loss in mouse models: mice were highly prone to develop tumors and mostly died during
their first year of life. In addition, p14ARF-null mouse embryonic fibroblasts (MEFs) can overcome
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the senescence crisis and proliferate continuously, and they also can be easily transformed by the Ras
oncogene [8]. Considering that p14ARF is a tumor suppressor it is not surprising that most human
cancers (colorectal, gastric, prostate, breast bladder, oral, hepatocellular, lung, leukaemia, glioblastoma,
and melanoma) are characterized by its inactivation mainly due to its promoter hypermethylation,
homozygous deletions and mutations (reviewed in [1]) or just reduced levels whose cause has not been
elucidated yet [9]. Due to its frequent alteration in cancer, population studies have been published
to show with the most recent genome-wide approaches, namely next generation sequencing and
array-CGH, the most recurrent p14ARF alterations in melanoma and leukaemia [10,11]. ARF protein
undoubtedly is a critical player in responding to an oncogenic insult, like hyperproliferative signal,
however its role in another cancer-related aberration, aneuploidy (loss or gain of entire chromosomes),
has not been punctually explored so far. Intriguingly, in the last decade experimental evidences of this
role of p14ARF or its murine orthologue p19ARF have been published. In fact, Weaver group showed
that ARF loss induced a small degree of aneuploidy in murine embryonic fibroblasts (MEFs) that was
the result of chromosome mis-segregation [12,13]. They also observed an increase of the aneuploidy
level when CENP-E loss was coupled with ARF loss [12]. On the other hand, we constantly observed
that p14ARF is involved in the cell response to the aneuploid phenotype triggered by the impairment of
different types of proteins, namely MAD2 and DNMT1 [14,15]. In particular, we showed that p14ARF
can respond either by arresting the cell cycle and entering senescence if necessary or by inducing
apoptosis [14–16]. Altogether, these results would let us think that the presence of p14ARF is critical
to halt aneuploidy. To this regard, we recently demonstrated that when CENP-E is reduced by 50%
and aneuploidy is consequently induced, HCT116 cells, where p14ARF is not expressed [17], are not
able to recover their euploidy. Conversely, normal IMR90 human fibroblasts, in which aneuploidy is
induced, restore their diploid chromosomal content in four weeks accompanied by a strong p14ARF
induction. HCT116 cells could finally recapitulate IMR90 cell behaviour and recover from aneuploidy
once they ectopically re-express p14ARF [18]. These evidences demonstrate that p14ARF is involved in
blocking the proliferation of aneuploid cells. However, we only analysed the effects of p14ARF ectopic
expression in a heterogenous population of HCT116 cells expressing different levels of p14ARF and we
did not investigate on the mechanism that allows the elimination of the aneuploid cells.
Here, we generated a monoclonal HCT116 cell line harbouring p14ARF cDNA integrated in
the genome specifically at ‘TTAA’ sites by the PiggyBac transposon vector system (ePB) (Figure 1A,B).
Briefly, HCT116 cells were co-transfected with the ePB vector carrying the p14ARF c-DNA and the vector
carrying the transposase enzyme (hyPB). Transfected cells were then selected with the antibiotic
blasticidin for ten days and then single colonies were picked, analysed and one positive clone was
chosen for further investigation. In the engineered HCT116 cells (HCT116 ePB cells), p14ARF cDNA
expression is under the control of the TET-On technology that allows activation of gene expression by
administration of doxycycline. By using a low dose of doxycycline (10ng/mL) we obtained the consistent
expression of p14ARF (Figure 1C–E). Reverse transcription PCR (RT-qPCR) analysis showed that after
doxycycline treatment the expression levels of p14ARF are higher in HCT116 ePB-p14ARF cells in
comparison to control HCT116 cells (Figure 1C). Moreover, immunofluorescence and Western blot
analyses showed the presence of the ectopic p14ARF protein (Figure 1D,E). Following p14ARF ectopic
re-expression we assessed whether in our model system cell proliferation and normal cell cycle
progression was affected. To this aim, we measured cell proliferation rates and analysed cell cycle by
cytofluorimetry. These experiments showed that p14ARF ectopic re-expression does not affect either
cell growth or cell cycle progression (Figure 1F,G).
Genes 2020, 11, 824 3 of 8
Genes 2020, 11, x FOR PEER REVIEW 3 of 8 
 
 
Figure 1. Generation and characterization of a monoclonal HCT116 cell line harbouring the p14ARF 
cDNA. (A) Experimental schematics of the monoclonal cell line generation. (B) Outline of the 
Figure 1. Generation and characterization of a monoclonal HCT116 cell line harbouring the p14ARF
cDNA. (A) Experimental schematics of the monoclonal cell line generation. (B) Outline of the PiggyBac
Genes 2020, 11, 824 4 of 8
transposon integration and Tet-on expression system; doxycycline (10ng/mL) was added to the cultured
cells for 24 h to switch on p14ARF expression. (C) RT-qPCR showing p14ARF transcript levels in HCT116
transfected cells; GAPDH was used as calibrator for the normalization. Standard error of the mean is
indicated. (D) Immunofluorescence and (E) western blot analyses confirmed p14ARF protein increase
in HCT116 ePB-p14ARF 24h after doxycycline treatment. (F) Cell proliferation analysis of HCT116-ePB
cells with and without doxycycline treatment. (G) Cytofluorimetric profiles of HCT116 ePB-p14ARF
cells. DNA was stained with Propidium Iodide (PI).
We then induced aneuploidy in these engineered HCT116 cells by treating them for 72 h with
the CENP-E inhibitor GSK923295 [19]. GSK923295 is an allosteric inhibitor, which specifically targets
the ATPase binding site of the CENP-E’s motor domain and non-competitively inhibits the ATPase
activity of CENP-E with high selectivity [20] but does not affect the protein stability, thus avoiding
any unwanted effect due to kinetochore architecture alteration. We treated the cells with a low dose
(5nM) of GSK923295 to allow a partial though efficient CENP-E inhibition without the cytotoxic effect
typical of this drug [18], to investigate the fate of the aneuploidy daughter cells following the p14ARF
induction/re-expression (Figure 2A,B). As expected, following CENP-E inhibition 65% of HCT116,
ePB-p14 cells become hypodiploid (compared to 18,5% in control cells (DMSO)). After doxycycline
treatment, and consequent p14ARF expression, the percentage of hypodiploid cells dropped down to
24% that is comparable to control cells. We had previously observed a similar behaviour in a population
of HCT116 cells harbouring exogenous p14ARF. In these cells, p14ARF was under the control of a Tet-off
system, therefore only when doxycycline was absent could p14ARF be expressed. We showed that when
CENP-E was reduced by RNA interference and there was no p14ARF expression (upon doxycycline
treatment), these cells became aneuploid (50%). However, when doxycycline was washed out and
thus p14ARF was expressed, the percentage of aneuploid cells was reduced from 50% to 22% [18]. In
addition, we also observed that, even if transiently transfected with a pcDNA3.1 expression vector,
p14ARF could partially reduce aneuploidy of CENP-E-depleted HCT116 cells from 73% to 56% [18].
Therefore, our new observations with a more accurate cell model system are perfectly in line with
our previous results showing that p14ARF ectopic re-expression restore the near-diploid phenotype of
HCT116 cells. These results confirm that p14ARF counteracts aneuploid cell generation/proliferation. It
is well established that p14ARF regulates cell cycle arrest and apoptosis, however it remains unclear
if p14ARF uses one or both mechanisms to fight aneuploidy [13,14,21]. To shed light on this we
evaluated cell cycle progression and apoptosis of HCT116 cells expressing p14ARF after treatment
with GSK923295 (Figure 2C–F). Propidium Iodide staining and the cytofluorimetric analysis clearly
showed that cells did not arrest their cell cycle when aneuploidy was induced by the treatment with
the CENP-E inhibitor GSK923295 and p14ARF was expressed. This made us think that apoptosis could
likely be the way through which p14ARF induces the clearance of the aneuploid cells. We hypothesized
thus that this could be the mechanism through which p14ARF helps the maintenance of chromosomal
stability. Hence, to identify the presence of apoptotic cells, we performed acridine orange and ethidium
bromide staining which discriminates live, apoptotic, and necrotic cells. By this mean we observed 25%
of apoptotic cells in HCT116 cells expressing p14ARF following GSK923295 treatment. These results
strongly suggest that p14ARF triggers the apoptotic pathway to halt aneuploid cell proliferation.
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Figure 2. p14ARF expression counteracts aneuploidy. (A) Schematics of the experiment, GSK923295
dissolved in DMSO (5nM) was given to the cells for 72 h. (B) Graphs and representative images showing
the results of the metaphase spread assay of HCT116 ePB-p14ARF cells (n = 30). (C) Cytofluorimetric
profiles of HCT116 ePB-p14ARF cells treated with GSK923295 and doxycycline. (D) Acridine orange
and ethidium bromide (AO/EtBr) double staining of HCT116 ePB-p14ARF cells. Representative pictures:
acridine orange (AO) permeates all cells and makes green, ethidium bromide (EB) is only taken up
by cells when cytoplasmic membrane integrity is lost and stains the nucleus of necrotic cells in red.
(E) The graph summarizes the percentage of living, apoptotic and necrotic HCT116 ePB-p14ARF cells.
Standard error of the mean is indicated.
Through this mechanism numerical chromosomal stability would be preserved in normal cells.
This is well-known during development of Drosophila melanogaster that indeed uses apoptosis
to eliminate aneuploid cells [22]. In addition, it has also been observed that, in mouse models of
pre-implantation chromosome mosaicism, the aneuploid cells were depleted from the embryo. This
depletion is due by a lineage-specific apoptosis during blastocyst [23]. Chromosome instability (CIN)
by itself is unfavourable for cell proliferation and thus detrimental. However, CIN, though it is not
sufficient, alone, for cell transformation, can facilitate cancer initiation and progression in particular
genetic backgrounds. Therefore, it is conceivable that adult cells can use apoptosis to counteract
aneuploidy similarly as cells do during development. Nevertheless, to our knowledge up to now
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there is no animal model showing this mechanism in adult cells. Similarly, we are not aware of
studies specifically describing the fate of cells with chromosome instability in patients that have p14ARF
mutations. Though, p14ARF role in cancer as tumor suppressor is vastly demonstrated. Noteworthily,
it has been noticed that patients with mutations in p14ARF have high risk of developing melanoma and
pancreatic cancer [24,25]. Furthermore, a thorough study of human cancers has highlighted that a large
number of human tumors use several mechanisms (both genetic and epigenetic) to fully inactivate
ARF [26]. Altogether, these evidences point out that p14ARF has a fundamental role in fighting cell
transformation and suggest that, due to the high frequency of deregulation in cancer, this role could
be played at early stages of cell transformation. We think that this could be due to p14ARF ability in
counteracting aneuploidy.
P14ARF was firstly identified as an alternate transcript of the CDKN2a locus, which is the second
most frequently mutated site in cancers after p53. Its tumor suppressor role as regulator of the cell cycle
and apoptosis has been indeed well established. Classically, a hyperproliferative signal that results
from an oncogenic insult triggers ARF activation. In this brief report, by confirming previous results,
we suggest that p14ARF can also respond to the onset of aneuploidy identification, thus providing an
additional function as a sentry of the euploid set of chromosomes. Remarkably, aneuploidy, i.e., an
abnormal number of chromosomes, is a hallmark of virtually all tumors. We observed that the absence
of p14ARF worsens the aneuploid phenotype of the cells, however it was generated. These cells, indeed,
cannot either block their cell cycle or enter apoptosis, and therefore, as a matter of fact, the possibility to
impede the proliferation of aneuploid cells is denied. The maintenance of aneuploidy can undoubtedly
contribute to malignant transformation. The presence/restoration of p14ARF, instead, allows cells to
counteract aneuploidy, most probably by sentencing the aneuploid cells to apoptosis. In fact, this
mechanism of aneuploid cell elimination by apoptosis has been observed during development. It is
conceivable that this function of ARF is an important part of its role as a tumor suppressor. Furthermore,
it is generally established that gene copy number correlates with gene expression. It is not too daring
to think that the imbalance of gene expression that is induced by aneuploidy could then generate
a signal resembling the hyperproliferative stress typically sensed by p14ARF. This, in turn, could
activate p53-dependent apoptosis. In conclusion, through this evidence, it is clear that p14ARF not only
responds to oncogene stimuli or to DNA damage, but also to an “aneuploidy signal” and protects
the cells from the maintenance of such aberrant and potentially dangerous condition.
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